Literature DB >> 25710421

Evolving beyond the vicious triad: Differential mediation of traumatic coagulopathy by injury, shock, and resuscitation.

Matthew E Kutcher1, Benjamin M Howard, Jason L Sperry, Alan E Hubbard, Anna L Decker, Joseph Cuschieri, Joseph P Minei, Ernest E Moore, Bernard H Brownstein, Ronald V Maier, Mitchell Jay Cohen.   

Abstract

BACKGROUND: A subset of trauma patients with critical injury present with coagulopathy, portending markedly worse outcomes. Clinical practice is evolving to treat the classical risk factors of hypothermia, hemodilution, and acidosis; however, coagulopathy persists even in the absence of these factors. We sought to determine the relative importance of injury- and shock-specific factors compared with resuscitation-associated factors in coagulopathy after trauma.
METHODS: Comprehensive demographic data, laboratory data, and outcomes data were prospectively collected from seven trauma centers over 8 years (November 2003 to August 2011) as part of the Inflammation and the Host Response to Injury Large-Scale Collaborative Program. A total of 1,537 critically injured patients with blunt trauma and hemorrhagic shock were analyzed to evaluate predictors of admission coagulopathy (international normalized ratio [INR] ≥ 1.3), multiorgan failure, and mortality.
RESULTS: Of 1,537 patients, 578 (37.6%) had admission INR of 1.3 or greater. Coagulopathic patients had more severe injury, more severe base deficit and lactate levels, as well as lower admission temperature, lower pH, and higher prehospital crystalloid volume (all p < 0.001). Coagulopathic patients required more blood products and mechanical ventilation and had higher rates of nosocomial infection, multiorgan failure, and mortality (all p < 0.02). Injury severity, temperature, and acidosis (all p < 0.02) independently predicted coagulopathy in multivariate analysis, with a significant interaction between lactate and prehospital crystalloid. In Cox regression models, however, coagulopathy itself remained an independent predictor of both multiorgan failure and mortality (p < 0.02) even when adjusted for injury severity, shock, and elements of the vicious triad.
CONCLUSION: Most patients with coagulopathy after trauma have mixed risk factors; however, coagulopathy has deleterious effects independent of injury severity, shock, and the vicious triad. Better understanding of the biochemical mechanisms of acute traumatic coagulopathy may facilitate biochemically targeted resuscitation strategies and improve outcomes. LEVEL OF EVIDENCE: Prognostic and epidemiologic study, level II.

Entities:  

Mesh:

Year:  2015        PMID: 25710421     DOI: 10.1097/TA.0000000000000545

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  13 in total

1.  Citrated kaolin thrombelastography (TEG) thresholds for goal-directed therapy in injured patients receiving massive transfusion.

Authors:  Gregory R Stettler; Joshua J Sumislawski; Ernest E Moore; Geoffrey R Nunns; Lucy Z Kornblith; Amanda S Conroy; Rachael A Callcut; Christopher C Silliman; Anirban Banerjee; Mitchell J Cohen; Angela Sauaia
Journal:  J Trauma Acute Care Surg       Date:  2018-10       Impact factor: 3.313

2.  Individual clotting factor contributions to mortality following trauma.

Authors:  Ryan C Kunitake; Benjamin M Howard; Lucy Z Kornblith; Sabrinah A Christie; Amanda S Conroy; Mitchell J Cohen; Rachael A Callcut
Journal:  J Trauma Acute Care Surg       Date:  2017-02       Impact factor: 3.313

3.  pH modulation ameliorates the red blood cell storage lesion in a murine model of transfusion.

Authors:  Alex L Chang; Young Kim; Aaron P Seitz; Rebecca M Schuster; Timothy A Pritts
Journal:  J Surg Res       Date:  2016-12-28       Impact factor: 2.192

4.  The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition.

Authors:  Donat R Spahn; Bertil Bouillon; Vladimir Cerny; Jacques Duranteau; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Marc Maegele; Giuseppe Nardi; Louis Riddez; Charles-Marc Samama; Jean-Louis Vincent; Rolf Rossaint
Journal:  Crit Care       Date:  2019-03-27       Impact factor: 9.097

5.  Algorithm for activation of coagulation support treatment in multiple injured patients--cohort study.

Authors:  D Brilej; D Stropnik; R Lefering; R Komadina
Journal:  Eur J Trauma Emerg Surg       Date:  2016-09-22       Impact factor: 3.693

6.  Predictors of mortality in pediatric urban firearm injuries.

Authors:  Kelly A Feldman; Jun Tashiro; Casey J Allen; Eduardo A Perez; Holly L Neville; Carl I Schulman; Juan E Sola
Journal:  Pediatr Surg Int       Date:  2016-09-28       Impact factor: 1.827

7.  Development of a Visual Analytics Tool for Polytrauma Patients: Proof of Concept for a New Assessment Tool Using a Multiple Layer Sankey Diagram in a Single-Center Database.

Authors:  Ladislav Mica; Cedric Niggli; Peter Bak; Avi Yaeli; Margaret McClain; Charles M Lawrie; Hans-Christoph Pape
Journal:  World J Surg       Date:  2020-03       Impact factor: 3.352

8.  The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition.

Authors:  Rolf Rossaint; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund A M Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Jean-Louis Vincent; Donat R Spahn
Journal:  Crit Care       Date:  2016-04-12       Impact factor: 9.097

Review 9.  Trauma-induced coagulopathy.

Authors:  Ernest E Moore; Hunter B Moore; Lucy Z Kornblith; Matthew D Neal; Maureane Hoffman; Nicola J Mutch; Herbert Schöchl; Beverley J Hunt; Angela Sauaia
Journal:  Nat Rev Dis Primers       Date:  2021-04-29       Impact factor: 65.038

10.  Prolonged resuscitation of metabolic acidosis after trauma is associated with more complications.

Authors:  Douglas S Weinberg; Arvind S Narayanan; Timothy A Moore; Heather A Vallier
Journal:  J Orthop Surg Res       Date:  2015-09-24       Impact factor: 2.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.